Vericel Co. (NASDAQ:VCEL) Shares Sold by Cynosure Group LLC

Cynosure Group LLC cut its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 37.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,986 shares of the biotechnology company’s stock after selling 2,937 shares during the period. Cynosure Group LLC’s holdings in Vericel were worth $274,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI bought a new position in shares of Vericel in the fourth quarter valued at $48,000. Smartleaf Asset Management LLC raised its position in shares of Vericel by 511.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,058 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Vericel by 8.4% during the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 183 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Vericel by 826.6% during the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,240 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Vericel in the 3rd quarter valued at $146,000.

Vericel Stock Down 1.9 %

Shares of NASDAQ:VCEL opened at $43.49 on Friday. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $63.00. The firm has a market capitalization of $2.18 billion, a P/E ratio of 724.95 and a beta of 1.78. The firm has a fifty day moving average of $52.05 and a two-hundred day moving average of $51.66.

Wall Street Analysts Forecast Growth

VCEL has been the subject of a number of analyst reports. Stephens reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Truist Financial reiterated a “buy” rating and set a $61.00 price target (down previously from $67.00) on shares of Vericel in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.29.

Insider Activity at Vericel

In related news, CEO Dominick Colangelo sold 26,592 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the transaction, the chief executive officer now owns 259,997 shares of the company’s stock, valued at approximately $11,902,662.66. This trade represents a 9.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,092 shares of company stock valued at $1,683,582. Insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.